

Special Issue

Tumor Immune Microenvironment in Gastric Cancers

Message from the Guest Editors

Gastric cancer is one of the most common and deadly digestive tract malignancies worldwide. The prognosis for patients with advanced gastric cancer is extremely poor, with a five-year overall survival rate of approximately 6% when diagnosed at advanced stages. Over the past decades, it has been increasingly evident that the tumor microenvironment (TME), which comprises cellular and non-cellular components that interact with proliferating tumor cells like the extracellular matrix, fibroblasts, immune cells, and endothelial cells, plays a crucial role in gastric cancer progression by creating an environment that is conducive to the survival of the cancer cells. The aim of this Special Issue is to collect original articles and reviews that aid to improve the understanding of the role of the tumor immune microenvironment in gastric cancer. This includes, but is not limited to, the roles of tumor-associated macrophages (TAMs), tumor-infiltrating lymphocytes (TILs), dendritic cells and myeloid-derived suppressor cells in the progression of gastric cancer and the possibilities of targeting these cells in gastric cancer.

Guest Editors

Dr. Chandrani Sarkar

Department of Pathology, University of South Alabama, Mobile, AL
36617, USA

Dr. Debanjan Chakroborty

Department of Pathology, University of South Alabama, Mobile, AL
36617, USA

Deadline for manuscript submissions

25 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/171271

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)